SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Association between the systemic inflammation response index and prognosis in lung cancer: a systematic review and meta-analysis.
Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe systemic inflammation response index (SIRI) is an emerging inflammation-immune indicator calculated from counts of neutrophils, monocytes, and lymphocytes. The potential prognostic value of SIRI in various tumors has been reported in several studies. However, updated and comprehensive evidence regarding its prognostic value in lung cancer (LC) remains insufficient. This study, through a systematic review and meta-analysis, intends to comprehensively analyze the relationship of SIRI with overall survival (OS) and progression-free survival (PFS) among individuals experiencing LC.
methodsCochrane Library, Web of Science, Embase, and PubMed were systematically searched from the commencement of the databases to October 2025. Cohort studies reporting the relation of SIRI with OS or PFS were included. Hazard ratios (HRs) alongside their 95% confidence intervals (CIs) were obtained, and a random-effects model was employed for data synthesis. Subgroup analysis, sensitivity analysis, and assessment of publication bias were conducted to evaluate the robustness of the findings.
resultsIn total, 27 studies involving 6195 patients with LC were incorporated into this meta-analysis, which revealed that high SIRI levels were significantly associated with poorer OS (HR = 1.83, 95% CI 1.58-2.13) and PFS (HR = 1.53, 95% CI 1.31-1.79). Differences in age, region, and cutoff value for SIRI were identified as the primary sources of heterogeneity. The sensitivity analysis indicated stable results, while the Egger's test demonstrated publication bias.
conclusionA higher SIRI level is significantly associated with adverse survival outcomes among individuals suffering from LC. As a simple and low-cost hematological marker, SIRI is potentially applied in the risk stratification and prognosis assessment of LC. In the future, prospective studies based on multicenter data and with a larger sample size, and a unified cutoff standard for SIRI are warranted to further corroborate the clinical utility of SIRI.
Indexed as
Identifiers
42081184What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.